---
document_datetime: 2026-01-19 11:16:26
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ziagen-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ziagen-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5149796
conversion_datetime: 2026-01-20 20:08:08.133801
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ziagen

Procedural steps taken and scientific information after the authorisation*

*Due e available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 15/01/2026                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000296309   | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - To address inconsistencies in Product Information documents and ensure align with the RMP documentation of Abacavir sulfate containing drug products. The Abacavir-related Patient Alert Card which is referenced in the RMP document as an additional risk minimisation and is being included in Annex II. D of the Product Information documents for consistency purposes. In addition the MAH has removed the local representative for UK(NI).   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|